Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -8.32% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.24
2
Flat results in Dec 24
3
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-88.12%
0%
-88.12%
6 Months
-87.74%
0%
-87.74%
1 Year
-72.27%
0%
-72.27%
2 Years
-74.58%
0%
-74.58%
3 Years
-87.55%
0%
-87.55%
4 Years
-89.07%
0%
-89.07%
5 Years
-91.46%
0%
-91.46%
AB Science SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.32%
EBIT Growth (5y)
9.25%
EBIT to Interest (avg)
-12.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.08
Sales to Capital Employed (avg)
-0.26
Tax Ratio
22.87%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.38
EV to EBIT
-9.33
EV to EBITDA
-10.13
EV to Capital Employed
-3.04
EV to Sales
73.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
1.00
1.60
-37.50%
Operating Profit (PBDIT) excl Other Income
-19.10
-16.80
-13.69%
Interest
3.40
0.10
3,300.00%
Exceptional Items
2.60
-0.20
1,400.00%
Consolidate Net Profit
-13.60
-14.50
6.21%
Operating Profit Margin (Excl OI)
-20,820.50%
-11,001.20%
-981.93%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is -37.50% vs 0.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is 6.21% vs 3.33% in Dec 2021
About AB Science SA 
AB Science SA
Pharmaceuticals & Biotechnology
AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
Company Coordinates 
Company Details
3 avenue George V , PARIS None : 75008
Registrar Details






